Lysogene Shifts Sanfilippo Focus To Subgroup Following Pivotal Trial Flop
As Cash Runway Dries Up
The French firm’s late-stage trial of its gene therapy candidate for Sanfilippo syndrome missed several endpoints but promising data from a cohort of young infants could help pave a way forward - if it can get more cash.
